Interactions between Poloxamer, PEOx-PPOy-PEOx, and Non-ionic Surfactant, Sucrose Monolaurate: A Study on Potential Allergenic Effect using Model Phospholipid Membrane

Author(s):  
Jin W. Kwek ◽  
S. Chakraborty ◽  
Kai C. Kuan ◽  
Wen C. Yeo ◽  
H. Yin ◽  
...  
2020 ◽  
Vol 65 (9) ◽  
pp. 1475-1483
Author(s):  
S. A. Alekseeva ◽  
I. V. Baranets ◽  
V. N. Beresnev ◽  
T. A. Nadervel ◽  
A. D. Kryuchkov ◽  
...  

2021 ◽  
Vol 7 (15) ◽  
pp. eabe6374
Author(s):  
Yulong Wei ◽  
Lesan Yan ◽  
Lijun Luo ◽  
Tao Gui ◽  
Biang Jang ◽  
...  

Treating osteoarthritis (OA) remains a major clinical challenge. Despite recent advances in drug discovery and development, no disease-modifying drug for knee OA has emerged with any notable clinical success, in part, due to the lack of valid and responsive therapeutic targets and poor drug delivery within knee joints. In this work, we show that the amount of secretory phospholipase A2 (sPLA2) enzyme increases in the articular cartilage in human and mouse OA cartilage tissues. We hypothesize that the inhibition of sPLA2 activity may be an effective treatment strategy for OA. To develop an sPLA2-responsive and nanoparticle (NP)–based interventional platform for OA management, we incorporated an sPLA2 inhibitor (sPLA2i) into the phospholipid membrane of micelles. The engineered sPLA2i-loaded micellar NPs (sPLA2i-NPs) were able to penetrate deep into the cartilage matrix, prolong retention in the joint space, and mitigate OA progression. These findings suggest that sPLA2i-NPs can be promising therapeutic agents for OA treatment.


Langmuir ◽  
2021 ◽  
Author(s):  
Fatma Pir Cakmak ◽  
Allyson M. Marianelli ◽  
Christine D. Keating

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jillian W. P. Bracht ◽  
Ana Gimenez-Capitan ◽  
Chung-Ying Huang ◽  
Nicolas Potie ◽  
Carlos Pedraz-Valdunciel ◽  
...  

AbstractExtracellular vesicles (EVs) are double-layered phospholipid membrane vesicles that are released by most cells and can mediate intercellular communication through their RNA cargo. In this study, we tested if the NanoString nCounter platform can be used for the analysis of EV-mRNA. We developed and optimized a methodology for EV enrichment, EV-RNA extraction and nCounter analysis. Then, we demonstrated the validity of our workflow by analyzing EV-RNA profiles from the plasma of 19 cancer patients and 10 controls and developing a gene signature to differentiate cancer versus control samples. TRI reagent outperformed automated RNA extraction and, although lower plasma input is feasible, 500 μL provided highest total counts and number of transcripts detected. A 10-cycle pre-amplification followed by DNase treatment yielded reproducible mRNA target detection. However, appropriate probe design to prevent genomic DNA binding is preferred. A gene signature, created using a bioinformatic algorithm, was able to distinguish between control and cancer EV-mRNA profiles with an area under the ROC curve of 0.99. Hence, the nCounter platform can be used to detect mRNA targets and develop gene signatures from plasma-derived EVs.


Sign in / Sign up

Export Citation Format

Share Document